Application YC di Eugit Therapeutics

Summer 2022Active

Eugit Therapeutics ha partecipato a Y Combinator nel batch Summer 2022 come azienda Healthcare. Sotto: cosa fa l'azienda, chi l'ha fondata e la sua application a YC, ricostruita domanda per domanda nel form reale di YC.

Batch YC: Summer 2022
Settore: HealthcareTherapeutics
Dimensione team: 2
Stato: Active
Lanciata: 2022

Founder

Nizar BatadaFounder

Cosa fa Eugit Therapeutics

Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).

Application YC di Eugit Therapeutics, ricostruita

Domanda per Y Combinator

Eugit Therapeutics, batch Summer 2022. Le vere domande del form, risposte da dati pubblici.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Eugit Therapeutics

Describe what your company does in 50 characters or less.

Enabling Tissue Targeting of Therapies

What is your company going to make? Please describe your product and what it does or will do.

We are building TAGHOME, a platform that uses T cell receptors to deliver drugs precisely to diseased tissues. This targets tissue-specific inflammatory diseases, aiming to improve safety and efficacy by reducing off-target toxicity. Our initial focus is on Inflammatory Bowel Disease patients in the U.S.

Where do you live now, and where would the company be based after YC?

We live and work in San Francisco and South San Francisco, CA, and will be based there after YC.

Explain your decision regarding location.

San Francisco is a biotech and synthetic biology hub with access to expertise and partners necessary for our therapeutic development. Being local makes clinical partnerships and team collaboration easier.

21 risposte in più nell'application completa

Founders, Progress, Idea, Equity, Curious, Batch Preference sono nella versione completa. Crea un account gratuito per aprirla in YC Insights, accanto a ogni altro batch YC.

Vedi domanda completa

Domande Frequenti

Questa è l'application YC reale di Eugit Therapeutics?

No. Y Combinator mantiene private le application inviate. Questa è una ricostruzione: le domande del form YC reale, a cui si è risposto usando i dati pubblici di Eugit Therapeutics (note di lancio, background dei founder, descrizione del prodotto). Mostra come un'azienda come Eugit Therapeutics si presenterebbe a YC, non il testo che hanno inviato.

A quale batch YC apparteneva Eugit Therapeutics?

Eugit Therapeutics apparteneva al batch Summer 2022 di Y Combinator.

Chi ha fondato Eugit Therapeutics?

Eugit Therapeutics è stato fondato da Nizar Batada.

Cosa fa Eugit Therapeutics?

Enabling Tissue Targeting of Therapies

Come leggo la ricostruzione completa della application?

Crea un account Round Funded gratuito. La versione completa di 26 risposte della application di Eugit Therapeutics, e di ogni altro batch YC, è in YC Insights.